- Home
- CNTX vs STXS Comparison
CNTX vs STXS Comparison
Compare CNTX & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | STXS |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 210.0M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CNTX | STXS |
|---|---|---|
| Price | $2.28 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.6M | 495.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $24.21 |
| Revenue Next Year | N/A | $29.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $1.54 |
| 52 Week High | $2.85 | $3.59 |
Technical Indicators
Market Signals| Indicator | CNTX | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 50.38 |
| Support Level | $2.06 | $2.04 |
| Resistance Level | $2.58 | $2.52 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 39.80 | 87.72 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.